In terms of (neo) adjuvant treatment, for HER2‐positive breast cancer, the most commonly used chemotherapy regimens in clinical practice were taxanes plus platinum (TCb) and anthracycline plus cyclophosphamide followed by taxanes (AC‐T). Here, ERBB2 is linked to breast carcinoma.